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Recently, gene-based cytokine treatment has been 
actively pursued as a new promising approach in treat-
ing cancer. In an effort to augment the efficiency of 
antitumor effect by cytokine-mediated immunother-
apy, we selected both interleukin (IL)-12 and 4-1BB 
ligand (4-1BBL) as suitable cytokines to fully activate 
the type-1 immune response. Coexpression of IL-12 
and 4-1BBL mediated by oncolytic adenovirus (Ad) 
greatly enhanced the antitumor effect. Further, syn-
ergistic enhancement in interferon (IFN)-γ levels were 
seen in mice treated with oncolytic Ad expressing both 
IL-12 and 4-1BBL. Next, to improve the overall antitu-
mor immune response, we coadministered IL-12- and 
4-1BBL-coexpressing oncolytic Ad with dendritic cells 
(DCs). Combination treatment of IL-12- and 4-1BBL-
coexpressing oncolytic Ad and DCs elicited greater anti-
tumor and antimetastatic effects than either treatment 
alone. Moreover, enhanced type-1 antitumor immune 
response and higher migratory abilities of DCs in tumors 
were also observed in the combination arms. The nature 
of the enhanced antitumor immune response seems to 
be mediated through the enhanced cytolytic activity 
of cytotoxic T lymphocytes (CTLs) and IFN-γ-releasing 
immune cells. Taken together, these data highlight the 
potential therapeutic benefit of combining IL-12- and 
4-1BBL-coexpressing oncolytic Ad with DCs and war-
rants further evaluation in the clinic.
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IntroductIon
Recent focus on the development of gene-based cancer therapy 
has been on utilizing cytokines, tumor suppressor, and apoptosis-
related genes as therapeutic genes.1,2 Central to this strategy, how-
ever, is the engineering of vectors that can efficiently and uniformly 
deliver the therapeutic gene of interest to solid tumors. By far, 
oncolytic adenoviral vector–mediated gene therapy is one of the 
most promising approaches, as confirmed by clinical observations 
and studies performed using animal tumor models.3–5 Recently, we 
have reported that oncolytic adenoviruses (Ads), which express 
multiple cytokines can elicit potent antitumor efficacy by coupling 
the lytic function of an oncolytic Ad with its ability to amplify har-
boring cytokine genes.6,7 Replicating oncolytic Ads were able to 
infect and deliver therapeutic genes to adjacent cells as well as to 
those infected initially. Further, they also induced high therapeu-
tic gene expression through increased adenoviral replication, and 
more importantly restricted the expression of therapeutic genes 
to cancer cells.
Interleukin (IL)-12 is a heterodimeric cytokine, which 
strongly promotes the differentiation of naive CD4+ T cells to 
type-1 T helper (Th1) phenotype and suppresses the expression 
of Th2 cytokines; and recently has been demonstrated to be one 
of the most efficient antitumor cytokines in experimental animal 
models.8 For example, oncolytic Ad–mediated local expression 
of IL-12 alone or with B7.1 co-stimulatory molecule generated 
tumor-specific immune responses and resulted in enhanced 
antitumor activity and higher incidences of tumor regressions.7 
Moreover, coexpression of B7.1 with IL-12 showed synergistic 
responses in promoting tumor-specific immunity, highlight-
ing the importance of co-stimulatory factor in full activation of 
T cells.
4-1BB ligand (4-1BBL) is a well-characterized co- stimulatory 
molecule expressed on antigen-presenting cells, including den-
dritic cells (DCs), macrophages, and B cells. Engagement of 
4-1BBL on antigen-presenting cells by its natural receptor, 4-1BB, 
a member of the tumor necrosis factor receptor superfamily, pro-
motes Th1 cell development and leads to increased expansion, 
cytokine production, and the development of cytolytic effector 
function of human T cells.9,10 Recent studies in vitro have demon-
strated that agonistic anti-4-1BB Abs and 4-1BBL co-stimulated 
proliferation and cytokine secretion in both CD4+ and CD8+ 
T cells.11 In addition, the treatment of anti-4-1BB Abs has also 
been shown to eradicate well- established tumors in mice.12
DCs are highly efficient and specialized antigen-presenting 
cells with a remarkable ability to stimulate naive T cells and 
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generate memory T cells. As such DC-based therapies have 
emerged as a promising anticancer therapy. DCs pulsed with 
 tumor-associated antigens in various forms, including whole-cell 
lysates, peptides, proteins, RNA, or DNA, have proven effective 
in  eliciting  protective and  therapeutic tumor antigen-specific 
immunity in murine models.13 DC-based vaccines have also been 
applied clinically for advanced-stage cancers, such as B-cell lym-
phoma, melanoma, prostate cancer, and renal cell carcinoma.14 
However the overall clinical benefit of these vaccines has been 
low; possibly owing to the impairment of transferred DCs’ func-
tion in cancer-bearing patients.15,16 Interestingly, the expression of 
mature DCs and major histocompatibility complex (MHC) class 
II markers was found to be significantly lower in breast cancer 
patients. In addition, DCs from cancer patients exhibited reduced 
ability to stimulate cytotoxic T lymphocytes (CTLs).15
In this report, we explored the potential benefit of combin-
ing IL-12- and 4-1BBL-coexpressing oncolytic Ad with DCs in 
the treatment of established tumors. We show that combination 
therapy of IL-12- and 4-1BBL-coexpressing oncolytic Ad and 
DCs elicited potent and synergistic antitumor effects. Further, 
enhanced Th1 antitumor immune response and higher DCs 
migratory abilities in tumors were also observed. These data 
highlight the potential therapeutic benefit of combining IL-12- 
and 4-1BBL-coexpressing oncolytic Ad with DCs preclinically 
and lays the foundation for examining these newly engineered 
Ads in the clinic.
results
characterization of Il-12 and/or 4-1BBl-expressing 
oncolytic Ads
Cultured mouse melanoma B16-F10 cells were infected with 
Ad-ΔB7/4-1BBL, Ad-ΔB7/IL-12, or Ad-ΔB7/IL-12/4-1BBL, along 
with control oncolytic Ad, Ad-ΔB7. Ad-ΔB7 is an oncolytic Ad 
with mutation in retinoblastoma binding sites of E1A and dele-
tion in E1B 19 kd and E1B 55 kd, showing significant cancer-
specific cytotoxicity and viral replication.17 The supernatant from 
infected cells was collected to assess IL-12 levels by enzyme-
linked immunosorbent assay (ELISA). As shown in Figure 1b, 
a dose-dependent increase in IL-12 was found in cells infected 
with either Ad-ΔB7/IL-12 or Ad-ΔB7/IL-12/4-1BBL, whereas 
no IL-12 production was found in cells infected with Ad-ΔB7. 
High levels of IL-12 were obtained even at a multiplicity of infec-
tion (MOI) of 25, and a higher expression was achieved until the 
MOI was increased up to 100. Interestingly, the level of IL-12 
expression by Ad-ΔB7/IL-12 is noticeably higher than those 
induced by Ad-ΔB7/IL-12/4-1BBL, suggesting that additional 
expression of 4-1BBL in the E3 region of Ad may negatively 
affect the expression of IL-12. The expression of 4-1BBL was also 
dose (MOI)-dependently enhanced in cells infected with either 
Ad-ΔB7/4-1BBL or Ad-ΔB7/IL-12/4-1BBL (Figure 1c). However, 
the expression of 4-1BBL was not adversely affected by addi-
tional expression of IL-12 in the E1 region, showing  equivalent 
 expression of 4-1BBL.
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Figure 1 schematic representation and kinetics of Il-12 and 4-1BBl expression of oncolytic adenoviruses expressing Il-12 and/or 4-1BBl. 
(a) Ad-ΔB7 contains mutated E1A (open star, mutation at Rb protein–binding site), but has deleted E1B 19 kd, E1B 55 kd (ΔE1B), and E3 region 
(ΔE3); The expression cassette for murine IL-12 and murine 4-1BBL was inserted into the E1 and E3 region of the Ad genome, respectively. Expression 
kinetics of (b) IL-12 and (c) 4-1BBL in B16-F10 cells after infection with Ad-ΔB7, Ad-ΔB7/4-1BBL, Ad-ΔB7/IL-12, or Ad-ΔB7/IL-12/4-1BBL at different 
MOIs. After 48 hours, supernatant and cell lysate was collected for the measurement of IL-12 by enzyme-linked immunosorbent assay and 4-1BBL 
by western blot analysis, respectively. Data represent the mean ± SE of three experiments. 4-1BBL, 4-1BB ligand; IL, interleukin; MOI, multiplicity of 
infection.
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therapeutic efficacy of oncolytic Ads expressing Il-12 
or/and 4-1BBl in established tumor model
To evaluate the therapeutic efficacy of IL-12- or/and 4-1BBL-
expressing oncolytic Ads in vivo, we intratumorally injected 
established B16-F10 melanoma tumors with Ad-ΔB7 [1 × 1010 
virus particles (VP)], Ad-ΔB7/4-1BBL (1 × 1010 VP), Ad-ΔB7/
IL-12 (5 × 109 VP), or Ad-ΔB7/IL-12/4-1BBL (5 × 109 VP). The 
reason why we have used half-dose of Ad for Ad-ΔB7/IL-12 or 
Ad-ΔB7/IL-12/4-1BBL group relative to Ad-ΔB7 or Ad-ΔB7/4-
1BBL group is that the antitumor effect of IL-12-expressing two 
oncolytic Ad were much better than either Ad-ΔB7 or Ad-ΔB7/4-
1BBL. Mice injected with phosphate-buffered saline (PBS) rap-
idly formed large tumors (over 3,000 mm3) and consequently 
were killed on day 12. In contrast, as shown in Figure 2a, all 
onco lytic Ads caused a significant inhibition of tumor growth 
(P < 0.01 versus PBS). At 12 days post-treatment, the mean 
tumor volume for the tumors treated with Ad-ΔB7, Ad-ΔB7/
IL-12, Ad-ΔB7/4-1BBL, or Ad-ΔB7/IL-12/4-1BBL were 1,265 ± 
155, 383 ± 27, 354 ± 71, and 136 ± 22 mm3, respectively, showing 
60, 88, 89, and 96% tumor growth inhibition in comparison to 
PBS-treated group. In relative comparison, the antitumor effi-
cacy of Ad-ΔB7/IL-12/4-1BBL was superior to that of tumors 
treated with either Ad-ΔB7/IL-12 or Ad-ΔB7/4-1BBL (P < 
0.05 versus Ad-ΔB7/IL-12; P < 0.01 versus Ad-ΔB7/4-1BBL). 
Moreover, all mice in the Ad-ΔB7/IL-12/4-1BBL group survived 
>30 days after initial viral injection (P < 0.01 versus Ad-ΔB7/
IL-12 or Ad-ΔB7/4-1BBL), whereas only 20% of the animals 
treated with either Ad-ΔB7/IL-12 or Ad-ΔB7/4-1BBL were via-
ble in the same time period (Figure 2b). This further supports 
the rationale of combining IL-12 and 4-1BBL to achieve maxi-
mal antitumor efficacy.
upregulated IFn-γ expression in tumor tissues
To assess whether interferon (IFN)-γ contributed to the observed 
antitumor efficacy induced by the oncolytic Ads expressing IL-12 
or/and 4-1BBL, its concentration in tumor tissues were measured 
by ELISA at day 5 post-treatment. As shown in Figure 3a, the 
level of IFN-γ was increased in the Ad-ΔB7/4-1BBL-, Ad-ΔB7/
IL-12-, and Ad-ΔB7/IL-12/4-1BBL-treated groups. In relative 
comparison, significantly higher IFN-γ levels were observed in 
tumors treated with Ad-ΔB7/IL-12/4-1BBL than those treated 
with Ad-ΔB7/4-1BBL or Ad-ΔB7/IL-12 (P < 0.01), implying that 
elevated IFN-γ maybe the reason for the observed enhanced anti-
tumor effect.
Generation of tumor-specific immune response by 
oncolytic Ads expressing Il-12 and/or 4-1BBl
To further assess whether IL-12- or/and 4-1BBL-expressing 
oncolytic Ads could induce tumor-specific immune responses 
against B16-F10 melanoma cells, IFN-γ enzyme-linked immu-
nosorbent spot (ELISpot) assay and 51Cr-release assay were 
independently performed. Splenocytes isolated from mice in all 
groups on day 5 after last viral injection were stimulated in vitro 
with irradiated B16-F10 cells for 5 days. Then the number of 
IFN-γ-secreting cells and the CTL activity was assessed by IFN-γ 
ELISpot assay and a standard 51Cr-release assay, respectively. As 
shown in Figure 3b, splenocytes obtained from mice treated 
with Ad-ΔB7/IL-12/4-1BBL group yielded significantly higher 
number of IFN-γ spots (P < 0.01) than those treated with either 
Ad-ΔB7/4-1BBL or Ad-ΔB7/IL-12. Significant CTL activity was 
also observed in mice receiving the IL-12-expressing oncolytic 
Ads (Ad-ΔB7/IL-12 and Ad-ΔB7/IL-12/4-1BBL; P < 0.01 ver-
sus Ad-ΔB7), whereas only a modest but reproducible CTL 
activity was detected in Ad-ΔB7- or Ad-ΔB7/4-1BBL-treated 
group (Figure 3c). In addition, the CTL activity of spleno-
cytes from mice treated with either Ad-ΔB7/IL-12 or Ad-ΔB7/
IL-12/4-1BBL was specific to B16-F10 tumors, as no CTL activ-
ity could be detected when Mus dunni mouse fibroblast cells 
were used as target cells in the 51Cr-release assay (data not 
shown). These results indicate that the potent antitumor effect 
seen with Ad-ΔB7/IL-12/4-1BBL in B16-F10 established tumor 
model (Figure 2) correlated positively with the tumor-specific 
immune response elicited by IL-12 and 4-1BBL expressed by 
the  oncolytic Ad.
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Figure 2 evaluation of therapeutic effect on established tumor. Mice with B16-F10 subcutaneous tumors were intratumorally injected with PBS, 
Ad-ΔB7 [1 × 1010 virus particles (VP)], Ad-ΔB7/IL-12 (5 × 109 VP), Ad-ΔB7/4-1BBL (1 × 1010 VP), or Ad-ΔB7/IL-12/4-1BBL (5 × 109 VP) three times. 
(a) Mean tumor volume following treatment with oncolytic adenoviruses. Data points represent the mean ± SE of the tumor size in each group (n = 
8–9 mice) at the indicated time points. The antitumor efficacy of Ad-ΔB7/IL-12/4-1BBL was superior to those of tumors treated with either Ad-ΔB7/
IL-12 or Ad-ΔB7/4-1BBL (P < 0.05 versus Ad-ΔB7/IL-12; P < 0.01 versus Ad-ΔB7/4-1BBL). (b) Survival of animals after treatment with oncolytic adeno-
viruses. The survival advantage for the Ad-ΔB7/IL-12/4-1BBL group was significant compared to Ad-ΔB7, Ad-ΔB7/IL-12, or Ad-ΔB7/4-1BBL (P < 0.01). 
*P < 0.05; **P < 0.01. 4-1BBL, 4-1BB ligand; PBS, phosphate-buffered saline; VP, virus particles.
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Histological and immunohistochemial assessment 
of tumor tissues treated with oncolytic Ads 
expressing Il-12 and/or 4-1BBl
To better understand the mechanism behind IL-12- and/or 
4-1BBL-expressing Ad-induced antitumor effect, histological and 
immunohitochemical analysis were performed. Tumors treated 
with either Ad-ΔB7/IL-12 or Ad-ΔB7/IL-12/4-1BBL were vis-
ibly smaller and had significantly higher immune cell infiltration 
(Figure 3d). Disruption of the tumor as a result of tumor necro-
sis was markedly evident in the tumors treated with Ad-ΔB7/
IL-12 or Ad-ΔB7/IL-12/4-1BBL as seen in the hematoxylin and 
eosin–stained sections. Immunohistochemical (IHC) analysis also 
confirmed the presence of both CD4+ and CD8+ T  lymphocytes in 
the tumors treated with Ad-ΔB7/IL-12 or Ad-ΔB7/IL-12/4-1BBL. 
Minimal to moderate level of CD4+ and CD8+ T lymphocytes were 
also detected in tumors treated with Ad-ΔB7 or Ad-ΔB7/4-1BBL. 
Moreover, CD86+ and CD11c+ DC population was substantially 
enhanced in sections derived from Ad-ΔB7/IL-12/4-1BBL-treated 
animals.
Injection of both Ad-ΔB7/Il-12/4-1BBl and dcs 
induces robust antitumor effect in vivo
With potential clinical applications in mind, we next compared 
whether oncolytic Ad expressing IL-12 and 4-1BBL would be 
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Figure 3 Generation of tumor-specific immune response by oncolytic adenoviruses expressing Il-12 and/or 4-1BBl. (a) Evaluation of 
IFN-γ expression in tumor tissues after treatment of IL-12- and/or 4-1BBL-expressing oncolytic adenoviruses. The level of IFN-γ was significantly 
increased in the Ad-ΔB7/IL-12/4-1BBL-treated mice than those in the mice treated with either Ad-ΔB7/IL-12 or Ad-ΔB7/4-1BBL (P < 0.01). 
Data points represent mean ± SE of three independent experiments. IFN-γ ELISpot (b) and Direct cytotoxicity (c) of splenocytes from B16-F10 
melanoma-bearing mice treated with PBS, Ad-ΔB7, Ad-ΔB7/4-1BBL, Ad-ΔB7/IL-12, or Ad-ΔB7/IL-12/4-1BBL. Tumor-specific IFN-γ secreting sple-
nocytes were detected by IFN-γ ELISpot assay. Ad-ΔB7/IL-12/4-1BBL-treated group showed higher number of IFN-γ spots than Ad-ΔB7/IL-12- or 
Ad-ΔB7/4-1BBL-treated groups (P < 0.01). Cytotoxicity was measured by a standard 4 hours 51Cr-release assay. CTL activity of Ad-ΔB7/IL-12/4-
1BBL-treated group was significantly increased than other groups (P < 0.01). Data points represent mean ± SE of three independent experiments. 
(d) Histological and immunohistochemical analysis. At 5 days following final administration of viruses, mice were killed and sections of paraffin 
embedded or frozen tumor tissue from each group were stained with hematoxylin and eosin (H&E) (top two rows) and analyzed for T cells with 
anti-CD4 monoclonal antibody (mAb) (third row) and anti-CD8 mAb (fourth row) or antigen presenting cells with anti-CD86 mAb (fifth row) and 
anti-CD11c mAb (bottom row). Necrotic area of Ad-ΔB7/IL-12- or Ad-ΔB7/IL-12/4-1BBL-treated groups were larger compared to that of other 
treatment groups. CD4+, CD8+, CD86+, and CD11c+ cells infiltrated deeply into tumors treated with Ad-ΔB7/IL-12 or Ad-ΔB7/IL-12/4-1BBL 
compared with other adenovirus-treated groups. (e) The average number ± SE of CD4+, CD8+, CD86+, and CD11c+-positive cells in microscopic 
field (×400). **P < 0.01 versus Ad-ΔB7/IL-12 group. 4-1BBL, 4-1BB ligand; CTL, cytotoxic T lymphocytes; ELISpot, enzyme-linked immunosorbent 
spot; IFN, interferon; IL, interleukin.
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more effective in combination with DCs. Quality control for DC 
preparation is mandatory in order to obtain reproducible and 
comparable study results. Therefore, the DC phenotype was first 
studied to determine maturation after the culture of DCs with 
tumor cell lysate and activation by lipopolysaccharide. As shown 
in Supplementary Figure S1a, the bone marrow–derived DCs 
cultured for 8 days exhibited the veiled dendrite morphology 
typical of DCs, showing the pricking and dendritic eminences 
on the cell surface. A representative phenotype for these DCs 
assessed by fluorescence-activated cell sorting analysis is shown in 
Supplementary Figure S1b. Activated DCs expressed high levels 
of maturation markers such as CD11c, CD40, CD80, CD86, MHC 
class I, and MHC class II, but negative for CD3ε (T-cell marker), 
CD19 (B-cell marker), and CD14 (monocyte marker).
The therapeutic efficacy of activated DCs in combination with 
Ad-ΔB7/IL-12/4-1BBL was next tested in established B16-F10 
tumor model (Figure 4). The tumor-bearing mice were treated 
with 2.5 × 109 VP of Ad-ΔB7/IL-12/4-1BBL, 1 × 106 DCs, or com-
bination of Ad and DCs. By day 15, tumors from mice treated 
with combination of Ad-ΔB7/IL-12/4-1BBL and DCs were signifi-
cantly smaller in size than DCs- or Ad-ΔB7/IL-12/4-1BBL-treated 
mice (all P < 0.01). Mice were killed when mean tumor volumes 
exceeded 3,000 mm3 and all mice treated with PBS or DCs suc-
cumbed to euthanasia by day 18. All mice receiving Ad-ΔB7/
IL-12/4-1BBL oncolytic Ad alone exhibited significant tumor 
growth delay, with three out of eight mice reaching its end point 
by day 28. In contrast, 100% of tumor-bearing mice treated with 
combination therapy of Ad-ΔB7/IL-12/4-1BBL and DCs were 
viable on day 28 (P < 0.01 versus DCs or Ad-ΔB7/IL-12/4-1BBL 
alone). Further, three out of eight mice achieved a complete remis-
sion and survived over 180 days. These data suggest that intra-
tumoral injection of Ad-ΔB7/IL-12/4-1BBL plus DCs elicited 
potent antitumor effect in a murine model with pre-established 
B16 melanoma.
tumor-specific immune response is associated with 
a treatment of Ad-ΔB7/Il-12/4-1BBl and dcs
To better understand the nature of the observed antitumor effects, 
splenocytes were collected from animals treated with PBS, DCs, 
Ad-ΔB7/IL-12/4-1BBL, or Ad-ΔB7/IL-12/4-1BBL plus DCs. As 
shown in Figure 5a, splenocytes from mice treated with Ad-ΔB7/
IL-12/4-1BBL plus DCs displayed significantly stronger tumor-
specific CTL activity against B16-F10 cells than those from either 
DCs- or Ad-ΔB7/IL-12/4-1BBL-treated mice (P < 0.01). The pres-
ence of tumor-specific immune response was also studied using 
an IFN-γ ELISpot assay. Splenocytes from the mice treated with 
Ad-ΔB7/IL-12/4-1BBL plus DCs showed significantly higher 
number of IFN-γ producing immune cells than those obtained 
from DCs- or Ad-ΔB7/IL-12/4-1BBL-treated mice (P < 0.01), sug-
gesting that combination therapy with Ad-ΔB7/IL-12/4-1BBL and 
DCs enhanced the Th1 immune response against B16-F10 tumor 
cells. Moreover, IFN-γ expression level in the tumor tissue treated 
with Ad-ΔB7/IL-12/4-1BBL plus DCs was higher than those of 
either DCs or Ad-ΔB7/IL-12/4-1BBL alone (P < 0.01). It is also 
worth noting that systemic levels of IFN-γ were undetectable, a 
finding that correlates with the absence of toxic effects in animals 
receiving the treatment.
Increased immune cell infiltration in tumor tissues 
treated with oncolytic Ads expressing Il-12 and/or 
4-1BBl and dcs
To gain insight into the potential mechanism of synergy between 
Ad-ΔB7/IL-12/4-1BBL oncolytic Ad and DCs, we analyzed infil-
tration of immune cells in the treated tumors. Histological exami-
nation revealed that a large number of immune cells were found 
within and around tumors in mice when intratumorally injected 
with Ad-ΔB7/IL-12/4-1BBL, DCs, or Ad-ΔB7/IL-12/4-1BBL plus 
DCs (Figure 5d, hematoxylin and eosin staining). In contrast, small 
number of immune cell infiltration was present in tumors treated 
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with PBS. IHC analysis confirmed the presence of both CD4+ and 
CD8+ T lymphocytes at the periphery of the excised tumor tissues 
treated with DCs alone, whereas significant lymphocyte infiltration 
inside of tumors treated with Ads alone or Ads plus DCs. Moreover, 
tumors treated with Ad-ΔB7/IL-12/4-1BBL plus DCs showed a sig-
nificantly higher number of CD11c+ and CD86+ DCs than tumors 
treated with either Ad-ΔB7/IL-12/4-1BBL or DCs alone.
To further determine DC migration to regional lymph 
nodes in vivo, we injected 1 × 106 green fluorescent protein 
(GFP)–expressing DCs alone or in combination with Ad-ΔB7/
IL-12/4-1BBL into pre-established B16-F10 tumor nodules 
24 hours after viral injection. The draining lymph nodes (DLNs) 
were then harvested 2 days after DC injection. The lymph node 
was prepared and stained with GFP-specific antibody (Ab). As 
shown in Figure 6, more GFP-expressing DCs were detected 
in the DLNs of tumor-bearing mice treated with combination 
therapy of DCs and Ad-ΔB7/IL-12/4-1BBL compared to DCs 
alone-treated group (P < 0.01), suggesting greater DC migra-
tory proficiency in mice treated with combination of DCs and 
Ad-ΔB7/IL-12/4-1BBL.
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Figure 5 Induction of tumor-specific immune response. Splenocytes obtained from mice treated with PBS, DCs, Ad-ΔB7/IL-12/4-1BBL, Ad-ΔB7/
IL-12/4-1BBL plus DCs were evaluated tumor-specific CTL activity and tumor-specific IFN-γ secreting ability. (a) Tumor-specific CTL activity per-
formed by 51Cr-release assay. Significantly enhanced CTL activity was observed in mice treated with Ad-ΔB7/IL-12/4-1BBL plus DCs than those 
treated with either DCs or Ad-ΔB7/IL-12/4-1BBL alone (P < 0.01). The effector:target (E:T) ratio indicated. Values are the mean ± SE of triplicate 
wells. (b) Tumor-specific IFN-γ secreting splenic immune cells. Mice treated with Ad-ΔB7/IL-12/4-1BBL plus DCs showed significantly increased 
number of IFN-γ producing immune cells than those treated with either DCs or Ad-ΔB7/IL-12/4-1BBL (P < 0.01). Results are representative of three 
independent experiments. (c) Evaluation of IFN-γ expression in tumor tissue after treatment of Ad-ΔB7/IL-12/4-1BBL and/or DCs. Significantly 
enhanced IFN-γ expression level was detected in tumor tissue treated with Ad-ΔB7/IL-12/4-1BBL plus DCs than those from other groups (P < 
0.01). Data points represent mean ± SE of three independent experiments. (d) Histology and Immunohistochemistry with H&E and immune cell 
markers. Massive necrotic areas were seen in tumors treated with combination therapy compared to other groups. Also large number of CD4+, 
CD8+, CD86+, and CD11c+ lymphocyte was infiltrated into tumor treated with Ad-ΔB7/IL-12/4-1BBL plus DCs compared to DC- or Ad-ΔB7/
IL-12/4-1BBL-treated groups. The results indicate that more effective antitumor immune response was induced in tumors treated with Ad-ΔB7/
IL-12/4-1BBL plus DCs than other groups. (e) The average number ± SE of CD4+, CD8+, CD86+, and CD11c+-positive cells in microscopic field 
(×400). **P < 0.01 versus Ad-ΔB7/IL-12/4-1BBL group. 4-1BBL, 4-1BB ligand; CTL, cytotoxic T lymphocyte; DC, dendritic cell; H&E, hematoxylin 
and eosin; IFN, interferon.
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Potent inhibition of tumor metastasis by treatment 
with Ad-ΔB7/Il-12/4-1BBl and dcs
The antimetastatic effect of combination therapy with Ad-ΔB7/
IL-12/4-1BBL and DCs was next evaluated using a spontaneous 
metastasis model. B16BL6 melanoma cells were implanted on 
the footpad subcutaneously and the primary tumors were sub-
sequently removed at 9 days postimplant, and tumor metastases 
to the lung were then measured. As shown in Figure 7a, B16BL6 
metastatic tumor volume in the lung was smaller in response to 
treatment with combination of Ad-ΔB7/IL-12/4-1BBL and DCs in 
comparison with Ad-ΔB7/IL-12/4-1BBL or DCs alone. The aver-
age relative lung weight from mice treated with Ad-ΔB7/IL-12/4-
1BBL alone, DCs alone, or combination of Ad-ΔB7/IL-12/4-1BBL 
and DCs was 353 ± 58, 281 ± 23, and 235 ± 12 mg, respectively, 
compared to PBS-treated control group (488 ± 33 mg) (P < 0.05, 
Ad-ΔB7/IL-12/4-1BBL plus DCs versus Ad-ΔB7/IL-12/4-1BBL 
alone) (Figure 7b). Taken together, the marked inhibition of spon-
taneous lung metastasis obtained with combination of Ad-ΔB7/
IL-12/4-1BBL and DCs suggests that intratumoral injection of 
oncolytic Ad expressing both IL-12 and 4-1BBL along with injec-
tion of DCs at the primary tumor site greatly reduced the forma-
tion of metastatic lesions at distal sites in this model system.
dIscussIon
Recently, gene-based cytokine treatment has been actively pur-
sued as a new promising approach in treating cancer. Among the 
different cytokines, IL-12 is of particular interest because of its 
 critical role in the stimulation of cell-mediated immune response. 
As systemic administration of IL-12 has been shown to induce 
dose-dependent and schedule-related systemic toxicity in both 
animal studies18 and in clinical trials,19,20 alternative strategies 
based on gene transduction within tumor cells with IL-12 genes 
have been investigated.21–23 Local delivery of IL-12 expressing 
fibroblast cells has been shown to suppress tumor growth and ani-
mals developed antitumor immune response.24 In addition, intra-
tumoral transfer of recombinant Ad expressing IL-12 resulted in 
substantial antitumor effect as well as increased survival rate.22 
More recently, we have shown the utility of IL-12-expressing 
onco lytic Ad in a cancer cell-restricted manner without accom-
panying toxicities.7
In an effort to augment the efficiency of antitumor effect by 
cytokine-mediated immunotherapy, we selected both IL-12 and 
4-1BBL as suitable immunostimulants to fully activate Th1 immune 
response. 4-1BBL has been shown to mediate  co-stimulation and 
expansion of CD8+ T cells greater than CD28 signaling.25 It is 
also been shown to strongly promote the differentiation of naive 
CD4+ T cells to Th1 phenotype and suppress the expression of 
Th2 cytokines. Moreover, 4-1BBL has also been demonstrated to 
activate T cells in the absence of B7.1/CD28 interactions.26,27
This study demonstrates that coexpression of IL-12 and 4-1BBL 
mediated by oncolytic Ad greatly enhanced the antitumor effect, 
compared with oncolytic Ads expressing IL-12 or 4-1BBL alone 
(Figure 2), suggesting that tumor-specific T-cell activation was 
involved in this increased antitumor efficacy. We also report syn-
ergistically enhanced IFN-γ levels, a Th1 cytokine that is impor-
tant for cell-mediated immunity, in mice treated with oncolytic 
Ad expressing both IL-12 and 4-1BBL (Figure 3a). The induction 
of IFN-γ after treatment with Ad-ΔB7/IL-12/4-1BBL Ad indi-
cates biologically active production of IL-12 by tumor cells and is 
exerting its characteristic immunoregulatory functions. Moreover, 
increased CTL activity and IFN-γ-expressing immune cells were 
detected in splenocytes taken from mice receiving intratumoral 
injection of Ad-ΔB7/IL-12/4-1BBL Ad relative to either Ad-ΔB7/
IL-12 or Ad-ΔB7/4-1BBL Ad (Figure 3b,c). These findings suggest 
that precursor CD4+ T cells become Th1 cells by the effective anti-
gen presentation of tumor cells that express 4-1BBL and that precur-
sor cytotoxic T cells (CD8+) are activated by Th1 cells. Consistent 
with these findings, IHC analysis also revealed a massive infiltra-
tion of both CD4+ and CD8+ T lymphocytes into tumors treated 
with Ad-ΔB7/IL-12/4-1BBL oncolytic Ad. In addition, we also 
observed a greater number of activated DCs infiltrated into these 
tumors (Figure 3d). This finding is in good agreement with recent 
reports by Pan et al., in which they demonstrate that 4-1BB activa-
tion in conjunction with IL-12 gene delivery increased DC prolif-
eration and tumor infiltration and enhanced the surface expression 
of MHC class II and  co-stimulatory molecules such as intercellular 
adhesion molecule-1, CD40, CD86, and 4-1BBL (ref. 28). Further 
these investigators also demonstrated that IL-12-activated natu-
ral killer cells upregulated 4-1BB expression by DCs through an 
IFN-γ-dependent pathway and that triggering of 4-1BB on DCs 
by injecting anti-4-1BB Ab resulted in an enhancement of tumor 
infiltration and maturation of DCs.28 These observations imply that 
high expression of IFN-γ in the Ad-ΔB7/IL-12/4-1BBL oncolytic 
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Figure 6 dc migration activity in mice treated with combination of 
Ad-ΔB7/Il-12/4-1BBl and dcs. Two groups of mice were used. In the 
first group (DCs alone), B16-F10 tumors were intratumorally injected 
with 1 × 106 DCs alone three times every 2 days. In the second group 
(DCs plus Ad-ΔB7/IL-12/4-1BBL), tumors were intratumorally injected 
with 5 × 109 VP of Ad-ΔB7/IL-12/4-1BBL oncolytic adenovirus. One day 
later, 1 × 106 DCs were injected intratumorally. (a) Two days after final 
DC administration, draining lymph nodes were harvested and green 
fluorescent protein (GFP) expression of DCs was determined. Original 
magnification ×400. (b) The mean number of migrated GFP+ DCs in 
the draining lymph nodes in microscopic files (×400). One representa-
tive experiment of three independent  experiments is shown. **P < 0.01. 
4-1BBL, 4-1BB ligand; DC, dendritic cell.
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Ad-treated tumors appeared to upregulate 4-1BB  activation on 
DCs through an IFN-γ-dependent pathway and the subsequent 
activation and tumor infiltration of DCs.
In recent clinical trials, DC-based therapies have yielded some 
objective responses and mechanistically tumor-specific immune 
responses were seen but the overall clinical outcomes have been 
disappointing. One of the reasons for this limitation maybe due 
to functional impairment of the DCs in the tumor microenviron-
ment that failed to induce a full antitumor immune response.29 
Research into optimization of protocols to provide effective in vivo 
activation stimuli for DCs was therefore actively pursued.30 In an 
attempt to improve the overall antitumor immune response, we 
examined a combination strategy in which IL-12- and 4-1BBL-
coexpressing oncolytic Ad was administered in conjunction 
with DCs. We show that this combination therapy significantly 
improved the therapeutic efficacy as well as survival. In particu-
lar, low dose (2.5 × 109 VP) of Ad-ΔB7/IL-12/4-1BBL oncolytic 
Ad elicited much better long-term survival (complete remission 
in three out of eight mice; Figure 4) when combined with DCs 
than double dose (5 × 109 VP) of Ad-ΔB7/IL-12/4-1BBL oncolytic 
Ad alone treatment (no remission in eight treated mice; Figure 2). 
The nature of the enhanced antitumor immune response seems to 
be mediated through the enhanced cytolytic activity of CTLs and 
IFN-γ-releasing immune cells, in agreement with recent study of 
Christopher et al. reporting that combination treatment of onco-
lytic herpes simplex virus 1 and DCs exhibits potent antitumor 
effect via enhancement of antitumor immunity.31 IL-12 has been 
shown to stimulate Th1-mediated cellular immune response, 
promote proliferation and maturation of CTLs and natural killer 
cells, and enhance the cytolytic function of these cells at least in 
part via the production of IFN-γ. It has also been reported that 
murine lymphoid DCs stimulated with IL-12 can release IFN-
γ.32 These observations suggest that the observed increase in 
IFN-γ seen in this study was mediated by both IL-12 expressed 
from Ad-ΔB7/IL-12/4-1BBL oncolytic Ad as well as the activated 
DCs. The activation of IL-12 receptor on DCs by IL-12 has been 
shown to promote nuclear localization of NF-κB, which increases 
the expression of MHC and co-stimulatory molecules. IL-12 also 
regulates DC immunostimulatory function. Thus, IL-12 produc-
tion from oncolytic Ad may serve as a positive stimulus to correct 
tumor-induced dysfunction in DCs.
Recently it has been demonstrated that activated natural killer 
cells can kill immature DCs,33 but also can induce the maturation 
of these DCs as well.34 In our study, it is possible that the high 
concentration of IFN-γ in tumor microenvironment induced by 
the combination treatment may have activated natural killer cells, 
which may have induced further maturation of DCs. Studies have 
also shown that the functionally impaired DCs found in tumor-
bearing animals and in advanced cancer patients correlated with 
the production of tumor-derived soluble factors, such as vascular 
endothelial growth factor, IL-10, and IL-6 that affect DC activa-
tion.35 IL-12 has been known to exhibit antiangiogenic effects that 
are mediated through IFN-γ induced production of monokine 
(by monocytes) and IFN-inducible protein 10 (by a variety of 
cells including endothelial cells).36 This suppression of angiogenic 
cascade in tumor milieu and suppression of VEGF expression 
induced by E1A in oncolytic Ad would further increase DC acti-
vation in tumor microenvironment.37
DCs exhibit an inherent migratory capability that is tightly 
linked to their activation/maturation status and seem to corre-
late interestingly with T-cell proliferation. As the mobilization of 
DCs from tumor tissues and their homing to DLNs is an essential 
component in activating a full antitumor immune response, the 
effect of IL-12 and 4-1BBL expressed by oncolytic Ad in tumor 
microenvironment on the migratory potential of the DCs was fur-
ther assessed. Injected DCs in tumors treated with combination 
therapy showed markedly enhanced migration toward the DLNs 
(Figure 6), indicating that the enhanced DC migratory  properties 
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Figure 7 therapeutic efficacy of combining Ad-ΔB7/Il-12/4-1BBl and dcs in spontaneous pulmonary metastasis model. (a) Representative 
lung macroscopic view of each group. Considerably less metastatic lesions were visible in lungs of mice treated with Ad-ΔB7/IL-12/4-1BBL and DCs. 
(b) Comparison of lung weight from each group. Significant inhibition of spontaneous lung metastasis was observed with combination of Ad-ΔB7/
IL-12/4-1BBL and DCs (P < 0.05 versus Ad-ΔB7/IL-12/4-1BBL alone). DC, dendritc cell; PBS, phosphate-buffered saline.
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induced by the combination therapy facilitates their aimed 
 movement toward and into the DLNs where DCs are recruited 
to activate T cells and initiate antitumor immune responses. This 
finding concurs with a recent report showing that genetic modifi-
cation of DCs with tumor-associated antigen-specific CD40 chi-
meric receptor enhances the ability of DCs in migrating to the 
DLNs.38 Moreover, Lapteva et al., also reported that transduction 
of immature DCs with a synthetic ligand-inducible CD40 recep-
tor (iCD40) enhanced DC migration,39 implying that DC matura-
tion is a key parameter of effective DC function.
Taken together, our study provides a proof of principle for 
the feasibility of using combined cytokine-expressing oncolytic 
Ads with DCs. Oncolytic Ad-induced tumor cell lysis would pro-
vide tumor antigens in an immunogenic form for presentation to 
injected DCs and the ability of 4-1BBL to mobilize DCs together 
with the high local concentration of antitumor immune cytokines 
such as IL-12 would provide an ideal tumor environment for the 
creation of potent antitumor immune response, resulting in the 
full activation of antitumor T-cell responses.
MAterIAls And MetHods
Cell lines and cell culture. Human embryonic kidney cell line 293, murine 
melanoma cell lines B16-F10 and B16BL6 (a metastatic variant of B16 mela-
noma cells), and mouse fibroblast cell line Mus dunni were purchased from 
the American Type Culture Collection (Manassas, VA). All cell lines were 
cultured at 37 °C in Dulbecco’s modified Eagle’s medium (Gibco, Grand 
Island, NY) supplemented with 10% fetal bovine serum (Gibco) and anti-
biotics, except for B16BL6 cells, which were cultured in modified Eagle’s 
medium (Gibco) supplemented with 5% fetal bovine serum, modified 
Eagle’s medium vitamin solution (1 mmol/l, product 11120-052; Gibco), 
penicillin (500 IU/ml), and streptomycin (50 μg/ml). All have tested nega-
tive for Mycoplasma using Hoeschst dye (MP Biomedicals, Irvine, CA), cell 
culture, and PCR.
Mice. C57BL/6 mice were obtained from SLC (Japan SLC, Tokyo, Japan). 
Mice were used at 6–7 weeks of age, and all animal studies were performed 
according to institutionally approved protocols at Yonsei University 
College of Medicine.
Ad vectors. Ad-ΔB7 is an Ad5-based E1B/E3-deleted oncolytic Ad with 
substitution in retinoblastoma binding sites of E1A (ref. 17). To gener-
ate an oncolytic Ad that expresses IL-12 at the E1 region of Ad-ΔB7, 
pCA14/E1AE1B19-IL-12 (ref. 6) E1 shuttle vector was linearized with 
NdeI digestion and then homologous recombination was induced 
in Escherichia coli BJ5183 with BstBI-digested Ad-ΔB7 to generate 
Ad-ΔB7-IL-12. To generate Ads that express 4-1BBL at the E3 region 
of Ad-ΔB7, the full-length mouse 4-1BBL complementary DNA was 
first cloned by reverse transcriptase-PCR using total RNA from bone 
 marrow–derived activated DCs. The 4-1BBL complementary DNA 
(53–982 nucleotides of National Center for Biotechnology Information 
L15435) was generated using following primer pairs (sense: 5′-ATGGA
TCCACCATGGACCAGCACACACTTG-3′; antisense: 5′-AGATAAGC 
TTTCATTCCCATGGGTTGTC-3′). The resulting PCR product was 
digested with BamHI/HindIII and cloned into the BamHI/HindIII-
digested pSP72ΔE3/CMV-polA (ref. 40) Ad E3 shuttle vector, gen-
erating pSP72-E3/4-1BBL E3 shuttle vector. This newly constructed 
pSP72-E3/4-1BBL E3 shuttle vector was then recombined with Ad-ΔB7 
and Ad-ΔB7-IL-12, generating Ad-ΔB7-4-1BBL and Ad-ΔB7-IL-12/4-
1BBL, respectively. All viral vectors were produced and propagated fol-
lowing standard procedures.41 Viral particle numbers were calculated 
from measurements of  absorbance at 260 nm (A260), where 1 absorbency 
unit is equivalent to 1012 VP/ml, and infectious titers were determined 
by limiting dilution in 293 cells.
Expression of 4-1BBL and IL-12. The expression of 4-1BBL was determined 
by western blot analysis. At 48 hours after infection of B16-F10 cells with 
Ad-ΔB7-4-1BBL or Ad-ΔB7-IL-12/4-1BBL at various MOIs, proteins in the 
cell extracts were separated by 10% sodium dodecyl sulfate– polyacrylamide 
gel electrophoresis and then transferred onto a nitrocellulose membrane. 
The membrane was incubated with primary monoclonal goat anti-mouse 
4-1BBL Ab (R&D Systems, Minneapolis, MN) and anti-β-actin Ab for 
1 hour. After incubation with secondary rabbit anti-goat IgG (H+L)-
horseradish peroxidase Ab (Southern Biotech, Birmingham, AL) for 45 
minutes at room temperature, filters were developed with the enhanced 
chemiluminescence system (Santa Cruz Biotechnology, Santa Cruz, CA). 
The expression of IL-12 was determined by ELISA as previously described.7 
Briefly, B16-F10 cells were infected with Ad-ΔB7-IL-12 or Ad-ΔB7-
IL-12/4-1BBL at various MOIs. At 48 hours after infection, IL-12 in the 
supernatant was determined with ELISA using anti-mouse IL-12 purified 
monoclonal Ab (ENDOGEN, Woburn, MA) and biotin-conjugated anti-
mouse IL-12 monoclonal Ab (ENDOGEN).
Generation of bone marrow–derived DC. Femur and tibia marrow cells 
from C57BL/6 mice were depleted of erythrocytes using red blood cell 
lysis buffer (Sigma, St Louis, MO). Cells were then cultured in complete 
RPMI 1640 media containing 10% fetal bovine serum, GM-CSF (10 ng/ ml; 
ENDOGEN), and IL-4 (10 ng/ml; ENDOGEN). On day 2, floating cells 
were discarded and the adherent cells were replenished with fresh com-
plete media. At day 4, culture supernatant was collected and centrifuged, 
and the cell pellet was resuspended in fresh RPMI 1640 containing cytok-
ines and returned to the original plate. On day 6, adherent DCs were incu-
bated with B16-F10 cell lysate (50 μg/ml) for 24 hours and then matured 
by addition of 1 μg/ml of lipopolysaccharide (Sigma) for 24 hours. Mature 
DCs were harvested and phenotypic markers of DC was confirmed by 
fluorescence-activated cell sorting analysis.
Established tumor models for in vivo antitumor effect. B16-F10 cells 
(5 × 105) were injected subcutaneously into the right abdomen of 6- to 
7-week-old male C57BL/6 mice. When the tumor volume reached around 
100 mm3, animals were sorted into groups with similar mean tumor vol-
umes and different doses of oncolytic Ads (Ad-ΔB7 or Ad-ΔB7/4-1BBL at 
1 × 1010 VP; Ad-ΔB7/IL-12 or Ad-ΔB7/IL-12/4-1BBL at 5 × 109 VP) were 
injected intratumorally three times every other day in a volume of 20 μl 
diluted in PBS. Tumor growth was monitored everyday by measuring two 
perpendicular tumor diameters using calipers. Tumor volume was calcu-
lated by the following formula: volume = 0.523 LW2, where L is length and 
W is width. Animals with tumors that were >3,000 mm3 were killed for 
ethical reasons.
IFN-γ detection in tissue homogenates. Tumor tissues were obtained from 
intratumoral treated mice by presented various viruses. After 5 days of 
final injection of viruses, tumors were grinded and liquefied in the PBS 
with protease inhibitor cocktail (cat no. P8340; Sigma). IFN-γ expres-
sion of treated tumors was determined by IFN-γ ELISA kit (ENDOGEN) 
according to the manufacturer’s instructions. Each experiment was carried 
out three to four times with three replicates in each group.
Tumor-specific IFN-γ ELISpot assay. The ELISpot assay was used to deter-
mine the B16-F10 tumor-specific IFN-γ-secreting T cells. As responder 
cells, splenocytes from mice in all groups on day 5 after final treatment 
were stimulated with irradiated B16-F10 in medium supplemented with 
recombinant human IL-2 (100 units/ml) for 5 days. Splenocytes were then 
serially diluted from 2 × 104 to 8 × 105 cells per well and incubated in 
anti-IFN-γ monocolonal Ab–coated plates. After 12 hours of incubation, 
plates were developed as previously described.7 After overnight drying at 
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room temperature in the dark, plates were evaluated. Each experiment was 
 carried out three to four times with three replicates in each group.
CTL assay. Viable splenocyte samples were isolated from Ad-ΔB7/
IL-12/4-1BBL and/or DCs treatment animals, and the cytolytic activity of 
CTL was determined as described previously.7 Percent-specific cytotoxic-
ity was determined from the formula: % Specific cytotoxicity = [(experi-
mental release − spontaneous release)/(maximum release − spontaneous 
release) × 100].
Histological and IHC staining. After treatment by Ad and/or DCs, tumors 
were harvested, snap-frozen, and 10-µm sections were prepared in Tissue 
Tek (Sakura Finetec, Torrance, CA). Tumor sections were blocked with 4% 
PBS–bovine serum albumin (Sigma) for 1 hour and incubated for 2 hours 
with appropriate dilution of biotin-labeled CD4 (purified rat anti-mouse 
CD4 monoclonal Ab; Pharmingen, San Diego, CA), CD8 (purified rat anti-
mouse CD8 monoclonal Ab; Pharmingen), CD86 (purified rat anti-mouse 
CD86 monoclonal Ab; Pharmingen), or CD11c (purified hamster anti-
mouse CD11c monoclonal Ab; Pharmingen) in 1% PBS–bovine serum 
albumin. Diaminobenzidine/hydrogen peroxidase (Dako, Carpinteria, 
CA) was used as the chromogen substrate. All slides were counterstained 
with Meyer’s hematoxylin.
Analysis of DC migration in vivo. To investigate the ability of DCs to migrate 
into regional lymph nodes in vivo, activated DCs were first transduced with 
GFP-expressing Ad at an MOI of 300. After 48 hours of transduction, 1 × 
106 DCs alone or in combination with Ad-ΔB7/IL-12/4-1BBL oncolytic Ad 
(5 × 109 VP) were intratumorally injected into established B16-F10 tumors 
three times every other day, in a sequence of Ad followed by DCs. At 48 
hours after final intratumoral DC injection, the DLNs were harvested and 
stained with GFP-specific Ab for the analysis of the presence of DCs.
Quantification of spontaneous pulmonary metastasis. The B16BL6 
spontaneous metastasis model was initiated by subcutaneously inocula-
tion of 1.5 × 105 tumor cells in 50 μl of Hank’s buffered salt solution into 
the right footpad. When tumors reached a volume of 200 mm3, the primary 
tumors were treated with PBS, DCs (1 × 106 cells), Ad-ΔB7/IL-12/4-1BBL 
(5 × 109 VP), or Ad-ΔB7/IL-12/4-1BBL plus DCs. Ad-ΔB7/IL-12/4-1BBL 
oncolytic Ad was intratumorally injected on days 1, 3, and 5, and DCs were 
injected into the intrapleural cavity on days 2, 4, and 6. On day 9, the pri-
mary tumor was then surgically excised by amputating the right hind leg 
below the knee under mild anesthesia. At 3 weeks after final treatment, 
lungs were harvested for assessment of metastatic tumor lesions.
Statistical analysis. The data were expressed as mean ± SE. Statistical anal-
yses of the data were performed using the two-tailed Student’s t-test (SPSS 
10.0 software; SPSS, Chicago, IL). P values of <0.05 were considered statis-
tically significant (*P < 0.05; **P < 0.01). Analysis of variance was used for 
multiple group comparison on antitumor effect examination.
suPPleMentAry MAterIAl
Figure S1. Microscopy and flow cytometry analysis of bone marrow 
derived DCs.
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